JP2008528565A - ネブライザー処方物 - Google Patents
ネブライザー処方物 Download PDFInfo
- Publication number
- JP2008528565A JP2008528565A JP2007552724A JP2007552724A JP2008528565A JP 2008528565 A JP2008528565 A JP 2008528565A JP 2007552724 A JP2007552724 A JP 2007552724A JP 2007552724 A JP2007552724 A JP 2007552724A JP 2008528565 A JP2008528565 A JP 2008528565A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- nebulizer
- ampoule
- ipratropium
- levalbuterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 238000009472 formulation Methods 0.000 title claims abstract description 95
- 239000006199 nebulizer Substances 0.000 title claims abstract description 55
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims abstract description 37
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims abstract description 37
- 229950008204 levosalbutamol Drugs 0.000 claims abstract description 37
- 229960001888 ipratropium Drugs 0.000 claims abstract description 36
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 19
- 208000006673 asthma Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 4
- 239000003708 ampul Substances 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 41
- 239000000812 cholinergic antagonist Substances 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 9
- 239000011780 sodium chloride Substances 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 10
- 238000011049 filling Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- -1 tiaproprium Chemical compound 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008181 tonicity modifier Substances 0.000 description 4
- 208000000884 Airway Obstruction Diseases 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- QUQOMXILDQSQPN-UHFFFAOYSA-M 3-benzyl-2,4-dimethyl-1,3-thiazol-3-ium;bromide Chemical compound [Br-].CC1=CSC(C)=[N+]1CC1=CC=CC=C1 QUQOMXILDQSQPN-UHFFFAOYSA-M 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)a)ネブライザー、および
b)薬学的に受容可能なキャリア中にレバルブテロールおよびイプラトロピウムを含む2.2ml以下の処方物を含有する、アンプル
を供給する工程、および
(2)該ネブライザーを使用して該処方物を投与する工程、を包含する。
(1)a)ネブライザー、および
b)該処方物を含有するアンプルであって、該処方物が、薬学的に受容可能なキャリア中にレバルブテロールおよびイプラトロピウムを含み、そして該アンプルが、2.2ml以下でありかつ0.3ml以上の該処方物を含有するアンプル
を供給する工程、および
(2)該ネブライザーを使用して該処方物を投与する工程、を包含する。
a)1.0から1.5mgのレバルブテロール、および
b)0.40から0.70mgのイプラトロピウム
のネブライザー処方物を含有する。
(1)治療に効果的な量のレバルブテロールおよび抗コリン作用薬の1回分用量を含有する容器;および
(2)該用量がどのように使用されるべきかの説明書、を含む。
以下の組成を有する大量ネブライザー処方物を調製した:
成分 量/濃度
レバルブテロール 0.625mg/ml
イプラトロピウム 0.25mg/ml
NaCl溶液(注入用) 9mg/ml
HCl pHを4.0に調節するため
以下の組成を有する大量ネブライザー処方物を調製した:
成分 量/濃度
レバルブテロール 0.83mg/ml
イプラトロピウム 0.33mg/ml
NaCl溶液(注入用) 9mg/ml
HCl pHを4.0に調節するため
Claims (33)
- 慢性閉塞性肺疾患(COPD)の治療を必要とする患者の治療方法であって、
(1)a)ネブライザー、および
b)薬学的に受容可能なキャリア中にレバルブテロールおよびイプラトロピウムを含む2.2ml以下の処方物を含有する、アンプル
を供給する工程、および
(2)該患者に該ネブライザーを使用して該処方物を投与する工程、
を包含する、方法。 - 前記アンプルが、0.5ml以上の前記処方物を含有する、請求項1に記載の方法。
- 前記アンプルが、約1.0から2mlの前記処方物を含有する、請求項1に記載の方法。
- 前記アンプルが、約1.5から2mlの前記処方物を含有する、請求項1に記載の方法。
- COPDまたは喘息の治療を必要とする患者の治療方法であって、該患者にネブライザーを介して、薬学的に受容可能なキャリア中にレバルブテロールおよびイプラトロピウムを含む処方物を投与する工程を包含する、方法。
- 前記患者が喘息を有する、請求項5に記載の方法。
- 前記患者がCOPDを有する、請求項5に記載の方法。
- 前記処方物が、約1.25ミリグラムのレバルブテロールを含有する、請求項5から7のいずれかの項に記載の方法。
- 前記処方物が、約0.5ミリグラムのイプラトロピウムを含有する、請求項5から8のいずれかの項に記載の方法。
- レバルブテロールおよびイプラトロピウムと薬学的に受容可能なキャリアとを含む処方物を含有する、充填されたアンプル。
- 2.2ml以下の前記処方物を含有する、請求項10に記載の充填されたアンプル。
- 2.0ml以下の前記処方物を含有する、請求項10に記載の充填されたアンプル。
- 約1.0から2mlの前記処方物を含有する、請求項10に記載の充填されたアンプル。
- ネブライザー処方物の容量を減少させることによって、該処方物の使用に際する患者のコンプライアンスを高める方法であって、
(1)a)ネブライザー、および
b)該処方物を含むアンプルであって、該処方物が、薬学的に受容可能なキャリア中にレバルブテロールおよび抗コリン作用薬を含み、そして該アンプルが、2.2ml以下でありかつ0.3ml以上の該処方物を含有する、アンプル
を供給する工程、および
(2)該ネブライザーを使用して患者に該処方物を投与する工程、
を包含する、方法。 - 前記アンプルが、2ml以下でありかつ0.5ml以上の前記処方物を含有する、請求項14に記載の方法。
- 前記処方物が、0.75から2.0mgのレバルブテロールを含有する、請求項14に記載の方法。
- 前記処方物が、1.0から1.5mgのレバルブテロールを含有する、請求項14に記載の方法。
- 前記処方物が、0.25から1.0mgのイプラトロピウムを含有する、請求項14から17のいずれかの項に記載の方法。
- 前記処方物が、0.4から0.7mgのイプラトロピウムを含有する、請求項14から17のいずれかの項に記載の方法。
- キットであって、
(1)治療に効果的な量のレバルブテロールおよび抗コリン作用薬と薬学的に受容可能なキャリアとの1回分用量を含有する容器;および
(2)該用量がどのように使用されるべきかの説明書
を含む、キット。 - 前記1回分用量が2.2ml以下の容量であり、そして前記説明書が、該1回分用量が、以前から公知の処方物より少ない時間で投与され得ることを説明している、請求項20に記載のキット。
- 前記説明書が、患者は、前記用量の投与を該用量の全体が投与されるまで続けるべきであると説明している、請求項20または21に記載のキット。
- 前記1回分用量が約2.0mlの容量である、請求項20から22のいずれかの項に記載のキット。
- 前記容量が約1.5mlである、請求項23に記載のキット。
- 前記抗コリン作用薬が、イプラトロピウム、チアプロプリウム、およびクロモリンナトリウムからなる群より選択される、請求項20から24のいずれかの項に記載のキット。
- 前記抗コリン作用薬が、イプラトロピウムである、請求項25に記載のキット。
- 高効率ネブライザーを用いて前記用量を送達するための説明書を含む、請求項20から26のいずれかの項に記載のキット。
- 前記ネブライザーが、ジェットネブライザーである、請求項27に記載のキット。
- 少なくとも25個の前記1回分用量を含む、請求項20から28のいずれかの項に記載のキット。
- 少なくとも120個の前記1回分用量を含む、請求項29に記載のキット。
- 気道疾患の治療のためのネブライザー処方物の製造におけるレバルブテロールおよびイプラトロピウムの使用。
- 前記疾患がCOPDである、請求項31に記載の使用。
- 前記疾患が喘息である、請求項31に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0501956.7A GB0501956D0 (en) | 2005-01-31 | 2005-01-31 | Nebulizer formulation |
PCT/GB2006/000309 WO2006079841A1 (en) | 2005-01-31 | 2006-01-30 | Nebulizer formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008528565A true JP2008528565A (ja) | 2008-07-31 |
Family
ID=34307728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007552724A Pending JP2008528565A (ja) | 2005-01-31 | 2006-01-30 | ネブライザー処方物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20080319006A1 (ja) |
EP (1) | EP1843750B1 (ja) |
JP (1) | JP2008528565A (ja) |
KR (1) | KR20070101292A (ja) |
CN (2) | CN101090709A (ja) |
AU (1) | AU2006208880B2 (ja) |
BR (1) | BRPI0606261A2 (ja) |
CA (1) | CA2596215A1 (ja) |
CZ (1) | CZ2007598A3 (ja) |
ES (1) | ES2441733T3 (ja) |
GB (1) | GB0501956D0 (ja) |
IL (1) | IL183578A0 (ja) |
IS (1) | IS8666A (ja) |
NO (1) | NO20073909L (ja) |
NZ (1) | NZ556714A (ja) |
WO (1) | WO2006079841A1 (ja) |
ZA (1) | ZA200704977B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018515428A (ja) * | 2015-05-18 | 2018-06-14 | グレンマーク・スペシャルティー・エスエー | 噴霧用のチオトロピウム吸入用溶液 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0700380D0 (en) | 2007-01-09 | 2007-02-14 | Breath Ltd | Storage Of Ampoules |
AU2009241628A1 (en) * | 2008-02-26 | 2009-11-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
CN102166213A (zh) * | 2009-11-12 | 2011-08-31 | 北京利乐生制药科技有限公司 | 以左旋沙丁胺醇与异丙托溴铵为活性成分的组合物 |
CN108883079A (zh) * | 2016-03-15 | 2018-11-23 | 广东东阳光药业有限公司 | 喷雾剂、喷雾装置以及喷雾组件 |
WO2021188809A1 (en) * | 2020-03-19 | 2021-09-23 | Cai Gu Huang | Inhalable formulation of a solution containing levalbuterol tartrate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02264730A (ja) * | 1989-04-04 | 1990-10-29 | Mitsutoshi Taira | Atll治療用吸入剤 |
JPH0892098A (ja) * | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
WO2003037159A2 (en) * | 2001-10-26 | 2003-05-08 | Dey, L.P. | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
WO2005000270A2 (en) * | 2003-06-27 | 2005-01-06 | Merck Patent Gmbh | Inhalable formulations for treating pulmonary hypertension and methods of using same |
JP2005502608A (ja) * | 2001-06-23 | 2005-01-27 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 抗コリン作用剤とコルチコステロイドとβ刺激剤を含む新規な医薬組成物 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3505337A (en) | 1967-12-22 | 1970-04-07 | Boehringer Sohn Ingelheim | N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof |
JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
US5362755A (en) * | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
DE69118359T2 (de) * | 1990-01-05 | 1996-08-14 | Sepracor,Inc., Marlborough, Ma. | Optisch reines r(-)albuterol zur behandlung von asthma |
NZ246050A (en) * | 1991-12-18 | 1995-12-21 | Astra Ab Formerly Aktiebolaget | Medicament containing formoterol and budesonide for treatment of respiratory disorders |
DK0673240T3 (da) * | 1992-12-09 | 1999-10-11 | Boehringer Ingelheim Pharma | Stabiliserede medicinske aerosolopløsningsformuleringer |
US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5603918A (en) * | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
US6571790B1 (en) * | 1997-05-12 | 2003-06-03 | Robert E. Weinstein | Method and device for organizing and coordinating the combined use of liquid medications for continuous nebulization for the treatment of respiratory disorders |
US6685691B1 (en) * | 1998-02-27 | 2004-02-03 | Boehringer Ingelheim Gmbh | Container for a medicinal liquid |
US7963955B2 (en) * | 1998-02-27 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Container for a medicinal liquid |
GB9807232D0 (en) * | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
JP4570251B2 (ja) * | 1998-07-24 | 2010-10-27 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
ATE234604T1 (de) * | 1998-08-04 | 2003-04-15 | Jago Res Ag | Medizinische aerosolformulierungen |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US7074388B2 (en) * | 1998-12-10 | 2006-07-11 | Kos Life Science, Inc. | Water stabilized medicinal aerosol formulation |
US6962151B1 (en) * | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6451289B2 (en) * | 2000-03-24 | 2002-09-17 | Sepracor Inc. | Albuterol formulations |
GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
BR0015884A (pt) * | 2000-05-22 | 2003-07-08 | Chiesi Farma Spa | Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
US6667314B2 (en) * | 2000-05-26 | 2003-12-23 | Pfizer, Inc. | Tropane derivatives useful in therapy |
SK286394B6 (sk) * | 2001-03-30 | 2008-09-05 | Jagotec Ag | Lekárske aerosólové prípravky |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US6455028B1 (en) * | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
WO2003035030A1 (en) * | 2001-10-24 | 2003-05-01 | Pari Gmbh | Kit for the preparation of a pharmaceutical composition |
US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
JP2003221335A (ja) * | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
US6702997B2 (en) * | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US20050175544A1 (en) * | 2001-10-26 | 2005-08-11 | Dey Lp | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US8084461B2 (en) * | 2001-10-26 | 2011-12-27 | Dey, L.P. | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US6974803B2 (en) * | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
US7084153B2 (en) * | 2002-04-12 | 2006-08-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising steroids and a novel anticholinergic |
US20040241103A1 (en) * | 2002-09-10 | 2004-12-02 | 3M Innovative Properties Company | Pharmaceutical aerosol compositions |
EP1417958A1 (en) * | 2002-11-08 | 2004-05-12 | Pari GmbH | Wet granulation process |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
RU2005129550A (ru) * | 2003-02-27 | 2006-07-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Антагонисты рецептора ccr-3 |
UA89751C2 (ru) * | 2003-03-20 | 2010-03-10 | Бёрингер Ингельхайм Фармасьютикалз, Инк. | Состав, который содержит сульфат альбутерола и бромид ипратропия, способ его получения и ингалятор |
WO2004084897A1 (en) * | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
US20060251711A1 (en) * | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
WO2005044187A2 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
US20050287077A1 (en) * | 2004-02-10 | 2005-12-29 | James E. Shipley | Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon |
TWI341836B (en) * | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
JP2007528408A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
WO2005122719A2 (en) * | 2004-06-08 | 2005-12-29 | Coifman Robert E | Ampules for small unit dose volumes of drug |
EP1809243B2 (de) * | 2004-07-02 | 2022-06-08 | Boehringer Ingelheim International GmbH | Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel |
WO2006025324A1 (ja) * | 2004-08-30 | 2006-03-09 | Ono Pharmaceutical Co., Ltd. | トロパン化合物およびそれらを有効成分として含有する医薬組成物 |
US20070264202A1 (en) * | 2004-09-09 | 2007-11-15 | Cipla Limited | Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent |
GB0422413D0 (en) * | 2004-10-08 | 2004-11-10 | Breath Ltd | High efficiency nebulisation |
WO2006059340A1 (en) * | 2004-12-03 | 2006-06-08 | Aparna Thirumalai Anandampilla | A resonating (alerting) metered dose inhaler |
US20060120967A1 (en) * | 2004-12-07 | 2006-06-08 | Qpharma, Llc | Solution forms of cyclodextrins for nasal or throat delivery of essential oils |
RU2440972C2 (ru) * | 2004-12-17 | 2012-01-27 | Сипла Лимитед | Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его |
FR2879574B1 (fr) * | 2004-12-17 | 2011-01-21 | Valois Sas | Dispositif de distribution de produit fluide. |
US20060140873A1 (en) * | 2004-12-27 | 2006-06-29 | Chang Heng W | Aerosol pharmaceutical compositions |
JP2008542332A (ja) * | 2005-05-31 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患治療用新規医薬組成物 |
WO2007020204A2 (en) * | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
US20070293460A1 (en) * | 2005-10-31 | 2007-12-20 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
WO2007095041A2 (en) * | 2006-02-09 | 2007-08-23 | Schering Corporation | Pharmaceutical formulations |
GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
-
2005
- 2005-01-31 GB GBGB0501956.7A patent/GB0501956D0/en not_active Ceased
-
2006
- 2006-01-30 EP EP06701649.3A patent/EP1843750B1/en not_active Revoked
- 2006-01-30 CZ CZ20070598A patent/CZ2007598A3/cs unknown
- 2006-01-30 ES ES06701649.3T patent/ES2441733T3/es active Active
- 2006-01-30 KR KR1020077017260A patent/KR20070101292A/ko not_active Application Discontinuation
- 2006-01-30 CN CNA2006800015509A patent/CN101090709A/zh active Pending
- 2006-01-30 JP JP2007552724A patent/JP2008528565A/ja active Pending
- 2006-01-30 US US11/815,085 patent/US20080319006A1/en not_active Abandoned
- 2006-01-30 BR BRPI0606261-0A patent/BRPI0606261A2/pt not_active IP Right Cessation
- 2006-01-30 CN CN2012100921125A patent/CN102631344A/zh active Pending
- 2006-01-30 WO PCT/GB2006/000309 patent/WO2006079841A1/en active Application Filing
- 2006-01-30 NZ NZ556714A patent/NZ556714A/en not_active IP Right Cessation
- 2006-01-30 AU AU2006208880A patent/AU2006208880B2/en not_active Ceased
- 2006-01-30 CA CA002596215A patent/CA2596215A1/en not_active Abandoned
- 2006-01-30 ZA ZA200704977A patent/ZA200704977B/xx unknown
-
2007
- 2007-05-31 IL IL183578A patent/IL183578A0/en unknown
- 2007-07-25 NO NO20073909A patent/NO20073909L/no not_active Application Discontinuation
- 2007-08-02 IS IS8666A patent/IS8666A/is unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02264730A (ja) * | 1989-04-04 | 1990-10-29 | Mitsutoshi Taira | Atll治療用吸入剤 |
JPH0892098A (ja) * | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
JP2005502608A (ja) * | 2001-06-23 | 2005-01-27 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 抗コリン作用剤とコルチコステロイドとβ刺激剤を含む新規な医薬組成物 |
WO2003037159A2 (en) * | 2001-10-26 | 2003-05-08 | Dey, L.P. | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
WO2005000270A2 (en) * | 2003-06-27 | 2005-01-06 | Merck Patent Gmbh | Inhalable formulations for treating pulmonary hypertension and methods of using same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018515428A (ja) * | 2015-05-18 | 2018-06-14 | グレンマーク・スペシャルティー・エスエー | 噴霧用のチオトロピウム吸入用溶液 |
Also Published As
Publication number | Publication date |
---|---|
ZA200704977B (en) | 2008-11-26 |
KR20070101292A (ko) | 2007-10-16 |
BRPI0606261A2 (pt) | 2009-06-13 |
CN101090709A (zh) | 2007-12-19 |
AU2006208880A1 (en) | 2006-08-03 |
CN102631344A (zh) | 2012-08-15 |
GB0501956D0 (en) | 2005-03-09 |
EP1843750A1 (en) | 2007-10-17 |
NO20073909L (no) | 2007-10-24 |
CA2596215A1 (en) | 2006-08-03 |
US20080319006A1 (en) | 2008-12-25 |
IL183578A0 (en) | 2009-02-11 |
IS8666A (is) | 2007-08-02 |
ES2441733T3 (es) | 2014-02-06 |
NZ556714A (en) | 2009-12-24 |
AU2006208880B2 (en) | 2010-08-26 |
CZ2007598A3 (cs) | 2007-10-17 |
WO2006079841A1 (en) | 2006-08-03 |
EP1843750B1 (en) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009528337A (ja) | ネブライザー処方物 | |
JP5072596B2 (ja) | 噴霧による薬剤送達のための方法およびキット | |
JP5863641B2 (ja) | 濃縮肥満細胞安定化用薬学的調合物 | |
JP2020023542A (ja) | 肺疾患治療のための肥満細胞安定剤 | |
JP2008528565A (ja) | ネブライザー処方物 | |
TWI758617B (zh) | 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途 | |
US20070276048A1 (en) | Unit dose formulations comprising an inhalable solution of albuterol | |
JP2014513091A5 (ja) | ||
ES2319887T3 (es) | Formulacion superfina de salmeterol. | |
ES2371601T3 (es) | Composición para inhalación. | |
TWI449523B (zh) | 福莫特羅(formoterol)及二丙酸倍氯米松(beclometasone dipropionate)之醫藥噴霧劑配方 | |
AU2020103517A4 (en) | Ibp- nebulizer: intelligent nebulizer for bronchitis patients | |
CN116196298A (zh) | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 | |
WO2014205030A1 (en) | Pulmonary administration of rotigotine | |
WO2023192445A1 (en) | Liquid formulations of indacaterol and glycopyrronium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081001 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120705 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120730 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120907 |